drugset / Trial / NCT00999401

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

NCT00999401

Phase 1 Completed 103 enrolled Cyclacel Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.

Timeline

Start
2009-04
Primary completion
2019-07-16
Completion
2019-08-13

Publications

  • Results Shapiro GI, et al. Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors. Cancer Res April 15, 2013 73; LB-202.

Drugs

EvaluationDrugModalityDoseRoute
Subject Seliciclib Small molecule Oral
Subject sapacitabine Small molecule Oral

Indications